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Conclusion: Significant	 symptomatic	 benefit	 and	 improvement	 in	QOL	was	 expe-




© 2021 The Authors. International Journal of Clinical Practice	published	by	John	Wiley	&	Sons	Ltd
2 of 9  |     HEALD Et AL.
1  | INTRODUC TION
Primary	hypothyroidism	affects	around	3%	of	people	in	Europe.1 
Although	 most	 people	 are	 treated	 satisfactorily	 with	 levothy-
roxine	 (l-	thyroxine)	up	 to	5%	of	 treated,	diagnosed	hypothyroid	
individuals	 report	 impaired	 quality	 of	 life	 (QOL),	 despite	 labo-
ratory	 thyroid	 function	 tests	 within	 the	 laboratory	 reference	
range.2	 A	 proportion	 of	 people	 with	 hypothyroidism	 who	 are	
seemingly	treatment	resistant,	are	prescribed	liothyronine	(l-	tri-	




although	not	 licenced	 in	 the	UK	 for	 treatment	 of	 hypothyroidism,	
are	prescribed	 for	a	 small	number	of	people	as	an	 imported	phar-
maceutical	product.	NDT	tablets	have	been	used	since	the	1890s.	






option	 than	 levothyroxine	 should	 be	 pursued	 in	 levothyroxine	 unre-
sponsive	individuals,	with	NDT	among	these	other	options	available.6,7
The	National	Institute	for	Health	and	Care	Excellence	(NICE),	in	
its	 clinical	 guideline	 on	 thyroid	 disease,8 did not recommend pre-
scription	of	NDT	for	people	with	hypothyroidism	whose	symptoms	
have	 not	 responded	 sufficiently	 to	 levothyroxine	 alone.	However,	
clinicians	have	had	to	take	a	pragmatic	approach	 in	relation	to	the	
management	of	patients	who	report	continuing	symptoms,	despite	
apparent	 adequate	 thyroid	 hormone	 replacement,	with	 some	pre-
scribing	NDT	as	a	less	costly	alternative	to	liothyronine.




























tre,	 consecutive	 clinic	 attendees	 with	 levothyroxine	 unresponsive	
hypothyroidism	were	prescribed	NDT,	either	in	the	form	of	ERFA® 









potential	 cause	 of	 the	 enduring	 symptoms	were	 ruled	 out	 as	was	
major	psychiatric	illness	or	personality	factors.










result	 in	 any	 benefit	 to	 the	 often	 very	 symptomatic	 pa-








the	 fact	 that	 the	majority	of	patients	 found	 these	 symp-
toms	to	be	significantly	alleviated,	can	be	viewed	as	sup-
portive	 evidence	 for	 the	 potential	 benefit	 of	NDT	when	
this	 is	prescribed	after	careful	consideration	of	other	dif-
ferential	diagnoses	and	other	treatment	options.







Patients’	 health-	related	 QOL	 and	 health	 utility	 were	 measured	
using	 validated	 questionnaires.	 These	 included	 the	 EuroQol13-	15 

























































Age	(y) 49.4 12.0 26-	77
Years since diagnosis 12.6 8.2 2-	40
Body	mass	index	(BMI)	(kg/m2) 30.1 6.5 22.7-	48.3
Dose	of	NDT	(mg) 123.5 29.5 60-	180
Pre-	NDT	TSH* (μ/L) 2.1 0.85 0.2-	9.8
Pre-	NDT	freeT4	(pmol/L) 18.9 4.2 14.6-	23.3





Current	freeT4	(pmol/L) 13.2 4.4 8.3-	30
*For	TSH,	we	report	geometric	mean	and	standard	deviation.
TA B L E  1  Characteristics	of	Cohort	of	
patients	treated	with	NDT	(n	= 31 with 3 
having	discontinued	the	NDT)
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3  | RESULTS
Thirty-	five	 patients	were	offered	NDT	 treatment,	 of	whom	 four	
declined and elected to continue with the liothyronine that they 
were	 purchasing	 on-	line	 and	 taking	 with	 levothyroxine.	 The	 re-
maining 31 patients were included in the prospective evaluation 




total	 thyroidectomy	 for	 toxic	goitre	and	one	person	a	history	of	
radioactive	 iodine	 induced	 hypothyroidism.	 Comorbidities	 in-
cluded	Chronic	Fatigue	Syndrome	in	6/31	patients	and	anxiety	or	
depression	(or	mixed	anxiety/depression)	in	six	individuals.	Other	
reported	 comorbidities	were	migraine	 (four	 individuals),	 irritable	
bowel	syndrome	(four	people),	vitamin	D	deficiency	(two	people)	
and	fibromyalgia	(two	people).
At	 baseline,	 all	 had	 laboratory	 thyroid	 function	 tests	within	
the	reference	range	for	free	thyroxine	(free	T4)	and	thyroid	stim-
ulating	hormone	(TSH)	but	reported	continuing	significant	symp-



















of	 experiencing	 palpitations	 on	 the	NDT.	 These	 2	 individuals	 had	
pre-	existing	intermittent	symptoms	of	palpations	but	no	diagnosed	























Utility score with only two showing a decrease between baseline 
and	 6-	month	 follow-	up	 (Figure	 2).	 Specifically	 EQ-	5D-	5L	 utility	




ThyPRO	 scores	 (Figure	 3)	 indicated	 an	 overall	 reduction	 in	
symptoms	and	QoL-	impairment	on	NDT.	ThyPRO	scores	showed	a	
consistent improvement across all domains including Depression (re-
duction	of	39.2;	95%	CI	26.5-	51.9),	Anxiety	(reduction	of	33.5;	95%	
CI	19.7-	47.4),	tiredness	(53.5;	95%	CI	43.5-	63.4),	Cognitive	Problems	




3.3 | Association between changes in ThyPRO 







3.4 | Association between BMI and NDT 
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3.5 | Patient reports
Individual	 descriptions	 of	 the	 response	 to	 NDT	 in	 relation	 to	 im-
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4  | DISCUSSION









aging people with treatment unresponsive hypothyroidism.





F I G U R E  3  Change	in	ThyPRO	ratings	over	time	from	baseline	pre-	NDT	initiation	to	6	months	post	NDT	initiation
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There	was	 improvement	 in	ThyPRO	scores	 regarding	 fatigue,	
as	 expected,	 but	 also	 scales	measuring	more	 complex	 (often	 re-
ferred	to	as	“distal”)	concepts	such	as	Impaired	Daily	Life,	in	rela-















randomised,	double-	blind,	crossover	study	of	Hoang	et	al9 who did 
not	 find	 any	differences	 in	 symptoms	or	 neurocognitive	measure-
ments	 between	 NDT	 and	 levothyroxine.	 However,	 their	 group	 of	





1880s)	 it	did	not	ever	need	to	go	through	the	 licencing	process	 in	
North	America—	it	was	classed	as	a	“grandfathered	drug”.	 It	has	al-
ways	 been	 approved	 by	 the	 Food	 and	Drug	Administration	 (FDA)	
but not licenced in the same way that many other drugs have been.5 
Nonetheless,	 today's	 manufacturing	 of	 NDT	 must	 comply	 with	
Good	 Manufacturing	 Practice	 as	 enforced	 by	 the	 FDA,	 and	 fol-
low	 the	 procedures	 and	 standards	 described	 in	 the	United	 States	
Pharmacopoeia.	Variable	quality,	which	impacted	on	earlier	clinical	
evaluations	of	NDT,	and	which	may	have	contributed	to	safety	con-
cerns,	might	 be	 less	 of	 a	 concern	with	 current	 branded	 products;	
although	some	maintain	that	because	of	the	“lack	of	standardisation”	
in	the	liothyronine	content,	the	use	of	Armour	Thyroid® should be 
avoided.19
There	 is	 emerging	 evidence	 that	may	 account	 for	 the	 efficacy	
of	 liothyronine	 (NDT	 contains	 a	 mixture	 of	 levothyroxine	 and	 li-
othyronine)	 in	 people	 who	 are	 symptomatically	 unresponsive	 to	
levothyroxine.20	Free	T3	is	the	endogenous	thyroid	hormone,	con-
verted	 from	 Free	 T4	 predominantly	 by	 local	 de-	iodination	 in	 tis-
sues.	 Increased	 free	T4	 levels,	 as	 seen	with	 levothyroxine	 therapy	
alone,	appear	to	inhibit	local	deiodination	except	in	the	pituitary,	so	
that	levothyroxine	monotherapy	may	result	in	TSH	inhibition	while	
reducing active thyroid hormone bioavailability in other tissues. 
Polymorphisms	 in	 the	 genetic	 coding	 of	 the	 deiodinase-	2	 (DiO2)	
enzyme,	present	in	13%	of	the	population,	have	the	potential	to	re-
duce	T3	levels	in	many	tissues,	including	the	brain,	without	affecting	
serum levels.21 This may represent a pharmacogenetic component in 
those	who	are	non-	responsive	to	levothyroxine.
The	body	of	opinion	continues	to	be	divided	as	to	whether	any	












and	 in	 size,	 the	 results	 lend	 support	 to	 the	 need	 for	 further	 clini-
cal assessment using rigorous research methods. The observed as-






dose-	dependent,	 supporting	 the	 importance	 of	 titration	 of	 NDT	
dose	while	monitoring	thyroid	function	tests	and	potential	cardiac	
symptoms	closely.	It	also	suggests	that	the	benefits	seen	with	NDT	
























This	 is	 a	 single	 centre,	 real	world,	observational	 study	with	no	
comparator group nor blinding. As such it is prone to bias and should 
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not	serve	to	change	clinical	practice.	Account	must	be	taken	of	an	





were administered to all attendees at our clinic and completed by 
all.	Importantly	all	the	individuals	were	screened	for	other	physical	
disorders	 as	 a	 cause	 of	 their	 symptoms	 and	 for	major	 psychiatric	
disorders.
5  | CONCLUSION
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